{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:37:29Z","timestamp":1791200249284,"version":"4.2.0"},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T00:00:00Z","timestamp":1282176000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Although the serotonin precursor 5\u2010hydroxytryptophan (5\u2010HTP) is marketed as a psychoactive nutritional supplement, knowledge is limited regarding the effects of exogenous 5\u2010HTP on brain activity. This study examined if oral administration of 5\u2010HTP to healthy adults impacted: (1) mood states, as measured by the Profile of Mood States (POMS); and (2) performance on the Iowa Gambling Task (IGT), a measure sensitive to alterations in frontocortical serotonin levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A sample of 46 undergraduates participated, and each received either two 50\u2009mg 5\u2010HTP capsules or placebos, and completed the IGT and POMS following an absorption period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>5\u2010HTP did not significantly alter mood states, but did impair performance on the IGT. Specifically, the 5\u2010HTP group performed more poorly than the placebo group during the first 20 trials of the IGT but did not differ from the placebo group on trials 21\u2013100. This suggests that oral 5\u2010HTP specifically impaired decision making under ambiguity but not under risk. Males also performed more poorly on the first 20 trials of the IGT, regardless of treatment group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Oral 5\u2010HTP is psychoactive at low doses. Decisions made under ambiguity may be differentially sensitive to increased serotonin release or associated reductions in frontocortical dopamine activity. Copyright \u00a9 2010 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.1139","type":"journal-article","created":{"date-parts":[[2010,8,27]],"date-time":"2010-08-27T05:20:54Z","timestamp":1282886454000},"page":"491-499","source":"Crossref","is-referenced-by-count":24,"title":["Oral administration of 5\u2010hydroxytryptophan (5\u2010HTP) impairs decision making under ambiguity but not under risk: evidence from the Iowa Gambling Task"],"prefix":"10.1002","volume":"25","author":[{"given":"Mathew H.","family":"Gendle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbe C.","family":"Golding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)01259-K"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-0277(94)90018-3"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/6.2.215"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.275.5304.1293"},{"key":"e_1_2_7_6_1","volume-title":"Iowa Gambling Task Professional Manual","author":"Bechara A","year":"2007"},{"key":"e_1_2_7_7_1","first-page":"271","article-title":"5\u2010Hydroxytryptophan: a clinically\u2010effective serotonin precursor","volume":"3","author":"Birdsall TC","year":"1998","journal-title":"Altern Med Rev"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neunet.2006.03.001"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/13803390500507196"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1037\/1040-3590.14.3.253"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tics.2007.10.011"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.1996.0125"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)00903-5"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)00902-3"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)00901-1"},{"key":"e_1_2_7_16_1","volume-title":"Principles of Neuropsychopharmacology","author":"Feldman RS","year":"1997"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.12.1568"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200204000-00012"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.4.466"},{"key":"e_1_2_7_20_1","volume-title":"Principles of Neural Science","author":"Kandel ER","year":"2000"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchemneu.2004.02.003"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1980.tb02451.x"},{"key":"e_1_2_7_23_1","first-page":"64","article-title":"Use of neurotransmitter precursors for treatment of depression","volume":"5","author":"Meyers S","year":"2000","journal-title":"Altern Med Rev"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002210000407"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/bhm066"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)00698-7"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0450-z"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2009.09.010"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00964729"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.06.004"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(82)90074-9"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9280.2005.01646.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdm.487"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000118469"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.1139","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.1139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T08:49:48Z","timestamp":1700556588000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.1139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1002\/hup.1139"],"URL":"https:\/\/doi.org\/10.1002\/hup.1139","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}